Company:  PERNIX SLEEP, INC.
Form Type:  8-K
Filing Date:  7/24/2012 
CIK:  0001339455 
Address:  440 STEVENS AVENUE,
SUITE 200
 
City, State, Zip:  SOLANA BEACH, California 92075 
Telephone:  (858) 876-6500 
Fiscal Year:  12/31 
Description of Business
Somaxon Pharmaceuticals, Inc. (�Somaxon�, �the Company�, �we�, �us� or �our�), is specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. In March 2010, the U.S. Food and Drug Administration, or FDA, approved our New Drug Application, or NDA, for Silenor� 3 mg and 6 mg tablets for the treatment of insomnia characterized by difficulty with sleep maintenance. Silenor was made commercially available by prescription in the United States in September 2010. Capital Resources Since inception, our operations have been financed primarily through the sale of equity securities and the proceeds from the exercise of warrants and stock options.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 5.1
BROKERAGE PARTNERS